# Bivalirudin Infusion for Ventricular Infarction Limitation

> **NCT02565147** · PHASE3 · TERMINATED · sponsor: **The Medicines Company** · enrollment: 78 (actual)

## Conditions studied

- Acute Myocardial Infarction

## Interventions

- **PROCEDURE:** PPCI
- **DRUG:** Bivalirudin
- **DRUG:** Heparin

## Key facts

- **NCT ID:** NCT02565147
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12-19
- **Primary completion:** 2016-06-14
- **Final completion:** 2016-06-14
- **Target enrollment:** 78 (ACTUAL)
- **Why stopped:** Futility at the interim analysis.
- **Last updated:** 2018-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02565147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02565147, "Bivalirudin Infusion for Ventricular Infarction Limitation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02565147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*